Clinnical Application value analysis of double contrast contrast-enhanced ultrasound in diagnosis and treatment of gastric cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400083433

Enrollment

Unknown

Registered

2024-04-24

Start date

2021-05-09

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

Gold Standard:Gastroscopic biopsy pathology or endoscopic/surgical pathology

Index test:Depth and extent of tumor

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: A. Preoperative T stage diagnosis of gastric cancer (1) Gastric cancer was pathologically diagnosed by gastroscopic biopsy; (2) No history of allergy to intravenous contrast agents; (3) Complete CT imaging examination; (4) Complete radical gastrectomy after admission; (5) neoadjuvant therapy for gastric cancer was not performed before surgery; (6) No previous history of other malignant tumors; B. Prognostic prediction of adjuvant therapy for gastric cancer (1) Gastric cancer was pathologically diagnosed by gastroscopic biopsy; (2) No history of allergy to intravenous contrast agents; (3) neoadjuvant therapy for gastric cancer was not performed before surgery; (4) Complete radical gastrectomy after admission; (5) Postoperative adjuvant treatment for gastric cancer; (6) No previous history of other malignant tumors; C. Evaluation and prediction of neoadjuvant therapy for gastric cancer (1) Gastric cancer was pathologically diagnosed by gastroscopic biopsy; (2) No history of allergy to intravenous contrast agents; (3) neoadjuvant therapy for gastric cancer was performed before surgery; (4) Complete radical gastrectomy after neoadjuvant therapy; (5) No previous history of other malignant tumors

Exclusion criteria

Exclusion criteria: (1) BMI=24; (2) Acute gastric dilation, gastric retention, severe intestinal obstruction, gastrointestinal perforation or suspected gastrointestinal perforation; (3) Lack of follow-up; (4) Poor quality of ultrasounic and CT images.

Design outcomes

Primary

Measure	Time frame
Depth of tumor invasion;Pathological complete remission;	—

Secondary

Measure	Time frame
Size of the tumor;Location of the tumor;Presence of the ulcer;	—

Countries

China

Contacts

Public ContactXiaoQing Pei

Sun Yat-sen University Cancer Center

peixq@sysucc.org.cn+86 20 8734 3212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026